Nucleix
Rehovot
About Nucleix
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $83.0M
- Last round: Series Unknown (Jan 2022)
- Website: nucleix.com
- Phone: +97289161616
Industries & Categories
Biotechnology, Health Care, Information Technology, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/nucleix-76741 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.